zanamivir


Also found in: Medical, Wikipedia.
Related to zanamivir: amantadine, Oseltamivir, Relenza

za·na·mi·vir

 (zə-nä′mə-vîr′)
n.
An antiviral drug, C12H20N4O7, that is used in inhalant form for the treatment and prevention of influenza.

zanamivir

(zəˈnæməˌvɪə)
n
a drug used to treat influenza
Translations

zanamivir

n zanamivir m
Mentioned in ?
References in periodicals archive ?
The present study evaluated the anti-influenza efficacy of the potent neuraminidase inhibitor zanamivir and ion channel blockers amantadine in avian species using chickens.
Oseltamivir and zanamivir are competitive inhibitors for the neuraminidase enzyme for the influenza virus.
Other NA inhibitors approved by the FDA for influenza infection include oseltamivir, which is orally administered, and zanamivir, which is inhaled.
Constantly evolving viral genome induces resistance against current anti- influenza drug regimens comprising newly developed drugs such Tamiflu, zanamivir, amantadine, etc.
The dosages for treatment with oseltamivir and zanamivir are provided in Table 1.
In the study, published April 10 in the Cochrane Database of Systematic Reviews, investigators analyzed data from 20 trials involving oseltamivir (Tamiflu[R]) and 26 trials involving zanamivir (Relenza[R]), encompassing a total of more than 24,000 people.
Susceptibility to the drugs zanamivir (GlaxoSmithKline, Uxbridge, UK), oseltamivir (Roche Diagnostics GmbH, Mannheim, Germany), peramivir (BioCryst Pharmaceuticals, Birmingham, AL, USA), and laninamivir (compound R-125489; Biota, Begbroke, UK) was assessed by fluorescent neuraminidase inhibition (NI) assay, by using inhibitor concentrations ranging from 0.
The two most commonly used antiviral drugs for treating influenza infections, oseltamivir and zanamivir, each provide a net benefit to patients compared with no treatment, concluded the authors of a meta-analysis of 74 influenza antiviral observational studies.
Antiviral treatment--typically oseltamivir (75 mg orally twice daily) or zanamivir (5 mg inhaled twice daily) for 5 days--should be administered promptly, ideally within 2 days of the onset of symptoms.
M2 PHARMA-January 20, 2011-GlaxoSmithKline begins Phase III study of IV zanamivir for hospitalised patients with influenza(C)2011 M2 COMMUNICATIONS